• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Senseonics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    3/12/26 4:06:26 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care
    Get the next $SENS alert in real time by email
    false 0001616543 0001616543 2026-03-11 2026-03-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): March 12, 2026

     

    SENSEONICS HOLDINGS, INC.
    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-37717   47-1210911
    (State or Other
    Jurisdiction of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    20451 Seneca Meadows Parkway
    Germantown, MD 20876-7005
    (Address of Principal Executive Office) (Zip Code)

     

    Registrant's telephone number, including area code: (301) 515-7260

     

    Not Applicable

    Former name or former address, if changed since last report

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock SENS Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Local Asset Purchase Agreements

     

    As disclosed in the Current Report on Form 8-K filed by Senseonics Holdings, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on January 2, 2026 (the “Original Form 8-K”), on December 31, 2025, the Company, Senseonics, Incorporated (“Senseonics Inc.” and together with the Company and its affiliates, the “Purchaser Parties”) and Ascensia Diabetes Care Holdings AG (the “Seller” and together with its affiliates, the “Seller Parties”) entered into a master asset purchase agreement (the “Master Asset Purchase Agreement”), pursuant to which, among other things, the Purchaser Parties acquired Seller’s and as applicable, Seller’s affiliates’, right, title and interest in and to certain assets related to Seller’s marketing, selling and distribution of the Eversense® product in the United States effective January 1, 2026.

     

    As described in the Original Form 8-K, the Master Asset Purchase Agreement also contemplated the negotiation and execution of a series of local asset purchase agreements (the “Local Purchase Agreements”) by and among the Seller and the Purchaser Parties and/or their affiliates, providing for the Purchaser Parties’ acquisition of certain additional assets related to Seller’s commercial Eversense CGM activities in Italy, Germany, Spain and Sweden (the “European Territories” and such assets, the “European Purchased Assets”) and, in connection therewith, the assumption of certain liabilities and obligations associated with the European Purchased Assets (the “European Assumed Liabilities” and together with the European Purchased Assets, the “European Asset Purchases”).

     

    On March 12, 2026, the Purchaser Parties and the Seller Parties entered into the Local Purchase Agreements, pursuant to which, among other things, the Purchaser Parties agreed to acquire Seller’s and as applicable, Seller Parties’, right, title and interest in and to the European Purchased Assets and to assume the European Assumed Liabilities, as contemplated by the Master Asset Purchase Agreement.

     

    Subject to the satisfaction or waiver of customary closing conditions, the closing of each of the European Asset Purchases is expected to occur on or before June 30, 2026 (collectively, the “European Closings”). In conjunction with each European Closing, the Purchaser Parties will make a cash payment to the Seller under the relevant Local Purchase Agreement of the respective Net Book Value based on the applicable European Purchased Assets and European Assumed Liabilities and subject to the terms and conditions set forth in the Master Asset Purchase Agreement and applicable Local Purchase Agreement.

     

    Each Local Purchase Agreement contains, including by incorporation from the Master Asset Purchase Agreement, customary representations, warranties, conditions and covenants, including but not limited to covenants concerning the conduct of business by the Seller Parties prior to the respective European Closing. Each party’s obligation to consummate the transactions contemplated by each Local Purchase Agreement is conditioned upon certain closing conditions, including the satisfaction or waiver of all the applicable conditions set forth in the Master Asset Purchase Agreement and each Local Purchase Agreement, the performance by the other party of its obligations and covenants under the Master Asset Purchase Agreement and each Local Purchase Agreement in all material respects, the absence of any injunction or other legal prohibitions preventing consummation of the transactions contemplated by each Local Purchase Agreement, the obtaining of certain regulatory clearances, consents or non-objection with respect to the transfer of tender contracts and the completion of certain required labor and employment processes. The Seller Parties and the Purchaser Parties have agreed to reasonably cooperate with each other and to use their respective commercially reasonable efforts to take or cause to be taken all actions, and to do or cause to be done all things, reasonably necessary to consummate the European Asset Purchases contemplated by each Local Purchase Agreement.

     

    The foregoing description of the Local Purchase Agreements is not complete and is qualified in its entirety by reference to the Local Purchase Agreements, each of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2026.

     

     

     

     

    Transition Services Agreement

     

    As described in the Original Form 8-K, in connection with entering into the Local Purchase Agreements, Senseonics Inc. and the Seller entered into a transition services agreement (the “Transition Services Agreement”), pursuant to which the Seller has agreed to provide Senseonics Inc. with certain transition services in the European Territories to support the preservation of the business, the preparation of the business for transition to Senseonics, and an orderly and uninterrupted transition of the business from Seller to new Senseonics legal entities in the European Territories, and provide for the continuity of commercial operations relating to the Eversense product in the European Territories, generally through dates up to June 30, 2026, subject to potential extension in the case of several of the shared services. Services to be provided under the Transition Services Agreement include support in the areas of logistics and ordering, payment and collections, claims processing, with respect to performance under tender contracts in the European Territories, IT and systems migration, business employee support, finance and operations support, regulatory compliance, and other agreed services. Senseonics has agreed to pay certain costs and service fees under the Transition Services Agreement.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which include, but are not limited to, statements regarding or implying the Company’s expectations and intentions regarding the effects of the Local Purchase Agreements and the transactions contemplated thereunder, the completion and timing of the European Closings, the progress and results of the transfer of the European Purchased Assets from the Seller Parties to the Purchaser Parties and other statements that do not relate solely to historical or current facts. In some cases, these statements include words like: “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to receive the required consents to consummate the European Asset Purchases in Italy, Germany, Spain and Sweden; the satisfaction of closing conditions precedent to the consummation of the European Asset Purchases, potential delays in consummating the European Closings; the execution costs to the Company of the transactions contemplated by the Local Purchase Agreements and the impact of these costs and other liabilities on the Company’s cash, property and other assets; and uncertainties in connection with the assumption of commercial responsibility for Eversense in the European Territories, including potential disruptions in relationships with employees, patients, prescribers, distributors or regulatory authorities. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in the Company’s most recent filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov.

     

    The forward-looking statements included in this report are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 12, 2026 SENSEONICS HOLDINGS, INC.
     
      By: /s/ Rick Sullivan
      Name: Rick Sullivan
      Title: Chief Financial Officer

     

     

     

     

    Get the next $SENS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SENS

    DatePrice TargetRatingAnalyst
    10/21/2025$9.00Hold
    Stifel
    8/27/2025$1.50Overweight
    Barclays
    7/15/2025$1.25Buy
    TD Cowen
    6/2/2025$1.10Buy
    H.C. Wainwright
    4/10/2025$2.00Outperform
    Mizuho
    7/19/2023$0.50Underperform
    Jefferies
    8/19/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SENS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Senseonics with a new price target

    Stifel resumed coverage of Senseonics with a rating of Hold and set a new price target of $9.00

    10/21/25 7:22:14 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Senseonics with a new price target

    Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50

    8/27/25 8:26:33 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Senseonics with a new price target

    TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25

    7/15/25 8:44:36 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase

    3/2/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

    MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on long-term, implantable Continuous Glucose Monitoring (CGM) systems for people with diabetes, today announced full availability of the twiist™ Automated Insulin Delivery (AID) System integrated with the Eversense® 365 CGM system across the U.S. Powered by Tidepool, twiist is the first AID system compatible with Eversense 365, the world's only one-year CGM. This powerful combination is a significant leap forward for the diabetes community, offering a t

    2/19/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Receives European Approval for Eversense 365, World's Longest-lasting Continuous Glucose Monitor

    GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system. Eversense 365 is the world's first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of the same year. The Eversense 365 CE Mark submission was prepared in compliance with the EU Medical Device Regulation (MDR) and is now approved for commercialization in 

    1/29/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Steven Edelman bought $65,500 worth of shares (10,000 units at $6.55), increasing direct ownership by 15% to 74,708 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    11/13/25 4:48:53 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sullivan Frederick T. bought $31,840 worth of shares (5,415 units at $5.88), increasing direct ownership by 4% to 157,028 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    11/10/25 7:40:12 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Roeder Douglas A bought $87,450 worth of shares (15,000 units at $5.83), increasing direct ownership by 18% to 99,727 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    11/10/25 7:40:13 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    SEC Filings

    View All

    Senseonics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    3/12/26 4:06:26 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Senseonics Holdings Inc.

    10-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    3/2/26 4:37:33 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    3/2/26 4:32:07 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fiorentino Edward was granted 2,398 shares, increasing direct ownership by 3% to 71,363 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    1/5/26 5:45:06 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Roeder Douglas A was granted 2,504 shares, increasing direct ownership by 3% to 102,231 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    1/5/26 5:45:10 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Prince Douglas S was granted 1,379 shares, increasing direct ownership by 2% to 56,743 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    1/5/26 5:45:11 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Financials

    Live finance-specific insights

    View All

    Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase

    3/2/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update

    Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2, 2026 GERMANTOWN, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for the fourth quarter of 2025 and provided a general business update. Recent Highlights & Accomplishments Generated preliminary unaudite

    1/12/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings, Inc. Reports Third Quarter Financial Results

    Generated Q3 revenue of $8.1 million, representing year-over-year growth of 90% Achieved a 160% increase in U.S. new patient starts over prior year Planning for the transition of CGM commercial responsibility from Ascensia Diabetes Care back to Senseonics GERMANTOWN, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights & Accomplishments: Generated revenue of $8.1 million in the third quarter of 2

    11/5/25 4:05:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $SENS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    2/13/24 5:13:59 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    7/7/23 4:35:55 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Senseonics Holdings Inc.

    SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)

    4/10/23 5:10:45 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care